Symposium
Tox 21 and New Approach Methodology (NAMs): Using Emerging Technologies to Improve Translational Research and Safety Assessment Predictions (jointly by SOT-NorCal & PBSS)
Speakers:
Kathryn Page (Clorox); Shichang Miao (ChemoCentryx); Thomas Hartung (The Bloomberg School of Public Health); Emily Reinke (U.S. Army Public Health Center); Suzanne Fitzpatrick (FDA); Pamela Lein (UC Davis); Ellen Berg (Eurofins); Will Proctor (Genentech)
Organizers:
Date:
2019-04-25
Time:
8:30-17:00 Pacific Time
Registration fee:
(USD): Regular (with lunch): $60; Students & Postdocs (with lunch): $0
Location:
South San Francisco Conference Center
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2019-04-23
(it will close sooner if the seating cap is reached)
About the Topic
Preliminary Agenda
Morning Session
7:30 am – 8:30 am Registration & Breakfast
8:30 am – 8:45 am Opening message from The NorCal & PBSS Presidents - Kathryn Page, PhD, DABT, Clorox; Shichang Miao, PhD, ChemoCentryx
8:45 am – 9:30 am Plenary Speaker: Alternative Methods for the 21st Century - Thomas Hartung, PhD, Johns Hopkins Bloomberg School of Public Health
9:30 am – 10:15 am From Experimental Concept to Regulatory Acceptance: The Success of Alternative Methods in Skin Sensitization Testing - Emily Reinke, PhD, DABT, U.S. Army Public Health Center
10:15 am – 10:30 am Coffee Break
10:30 am – 11:15 am Consumer Product Safety Assessment: An Alternative Approach - Kathryn Page, PhD, DABT, Clorox
11:15 am – 12:00 pm Predictive Toxicology for Regulatory Decisions: Implementing New Approaches at FDA - Suzanne Fitzpatrick, PhD, FDA
12:00 pm – 1:30 pm Lunch Break: Lunch with Experts, Posters
Afternoon Session
1:30 pm – 1:45 pm Chapter announcements and acknowledgements
1:45 am – 2:05 am NorCal Student Award presentation: TBD
2:05 pm – 2:45 pm In Vitro and Alternative Models of Neurotoxicity: Opportunities and Challenges for Neurotoxicity Testing - Pamela Lein, PhD, DABT, UC Davis
2:45 pm – 3:00 pm Coffee Break
3:00 pm – 3:45 pm Applying Human-based Phenotypic Profiling in Early Drug Discovery - Ellen Berg, PhD, Eurofins
3:45 pm – 4:30 pm Industry Perspective on Evaluating, Qualifying, and Implementing Complex In Vitro Models to Support Drug Discovery - Will Proctor, PhD, DABT, Genentech
4:30 pm – 6:00 pm Reception & Networking
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
|
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
|
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|